Aclaris Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACRS research report →
About the company
Aclaris Therapeutics, Inc. , a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services.
- CEO
- Neal S. Walker
- IPO
- 2015
- Employees
- 73
- HQ
- Wayne, PA, US
Price Chart
Get TickerSpark's AI analysis on ACRS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $671.71M
- P/E
- -9.95
- P/S
- 80.28
- P/B
- 4.99
- EV/EBITDA
- -9.13
- Div Yield
- 0.00%
- Gross Margin
- 76.34%
- Op Margin
- -961.91%
- Net Margin
- -832.58%
- ROE
- -55.89%
- ROIC
- -46.81%
- Revenue
- $7.83M · -58.19%
- Net Income
- $-64,923,000 · 50.84%
- EPS
- $-0.53 · 69.01%
- Op Income
- $-76,375,000
- FCF YoY
- -133.28%
- 52W High
- $5.88
- 52W Low
- $1.46
- 50D MA
- $4.84
- 200D MA
- $3.56
- Beta
- 0.77
- Avg Volume
- 1.65M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Mehra Anand | other | 11,580 |
| Jun 4, 26 | SCHIFF ANDREW N | other | 42,350 |
| Jun 4, 26 | Mehra Anand | other | 42,350 |
| Jun 5, 26 | SCHIFF ANDREW N | other | 11,580 |
| Jun 4, 26 | SCHIFF ANDREW N | other | 10,987 |
| Jun 4, 26 | Mehra Anand | other | 10,987 |
| Jun 5, 26 | Mehra Anand | other | 11,580 |
| Jun 5, 26 | SCHIFF ANDREW N | other | 11,580 |
| Jun 5, 26 | Molineaux Christopher P. | other | 11,580 |
| Jun 5, 26 | Humphries William D. | other | 11,580 |
Our ACRS coverage
Recent articles, reports, and earnings notes.
Vesicor Therapeutics Is Going Public via SPAC — Here’s the Setup
Vesicor Therapeutics, a preclinical oncology gene-therapy company, is going public via merger with Black Hawk Acquisition Corp (BKHA). The deal is still pending in the latest June 2026 filing, and the setup hinges on whether redemptions and dilution leave enough capital for a real biotech runway.
Should You Buy the Parabilis Medicines IPO? Here's the Setup
Parabilis Medicines (NASDAQ: PBLS) is expected to list on 2026-06-10, with shares priced at $17.00 to $19.00. The company is offering 25,000,000 shares and is targeting a $546,250,000 market cap. The bull case is a differentiated oncology platform; the bear case is a clinical-stage biotech with no disclosed commercial revenue.
Want a deeper read on ACRS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
zacks.com · Jul 1
3 Penny Stocks Under $5 Backed by Real Revenue Growth
marketbeat.com · Jun 23
3 Penny Stocks Under $5 Backed by Real Revenue Growth
marketbeat.com · Jun 20
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
marketbeat.com · Jun 4
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
globenewswire.com · May 28
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
seekingalpha.com · May 14
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
globenewswire.com · May 8
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
zacks.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Community Sentiment
Be the first to call it — is ACRS a buy or a sell from here?